Combination Therapy Approaches for Cancer Treatment
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 342
Special Issue Editors
Interests: oxidative stressors and lipid mediators; cancer pharmacology and chemoprevention; anticancer therapeutics and immunomodulation; photobiology and environmental factors; cellular signaling pathways in tumor resistance mechanisms; antitumor immune responses
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to a Special Issue on “Combination therapy approaches for cancer treatment”. The treatment of human malignancies invites ongoing challenges, including the development of tumor resistance mechanisms to conventional therapeutic agents. Thus, combination therapy approaches are being explored to target tumor resistance mechanisms and counter-regulatory pathways involved in impeding the efficacy of cancer therapies to improve the overall responses of therapeutic agents, including survival benefits.
This Special Issue aims to publish original research articles or reviews on combination therapy approaches for cancer treatment, which fits with the journal’s scope regarding drug targeting and interdisciplinary research, involving, but not limited to, biomedical sciences and cell biology.
In this Special Issue, research areas may include (but are not limited to) the following: a combination of chemotherapeutic agents, repurposed drugs, dietary phytochemicals, targeted therapy, and immunotherapy approaches on any cancer models.
We look forward to receiving your contributions
Dr. Ravi P. Sahu
Dr. Anita Thyagarajan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- combination therapy approaches
- cancer chemoprevention
- chemotherapeutic agents
- cell signaling pathways
- dietary phytochemicals
- tumor resistance mechanisms
- repurposed drugs
- targeted therapy
- immunotherapy
